113 related articles for article (PubMed ID: 10090430)
1. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa.
Lorenz TJ; Macdonald F; Kitt MM
Clin Ther; 1999 Jan; 21(1):128-37. PubMed ID: 10090430
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
3. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Tcheng JE
Am J Cardiol; 1997 Aug; 80(4A):21B-28B. PubMed ID: 9291242
[TBL] [Abstract][Full Text] [Related]
4. Development of eptifibatide.
Scarborough RM
Am Heart J; 1999 Dec; 138(6 Pt 1):1093-104. PubMed ID: 10577440
[TBL] [Abstract][Full Text] [Related]
5. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
O'Shea JC; Tcheng JE
Expert Opin Pharmacother; 2002 Aug; 3(8):1199-210. PubMed ID: 12150697
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
[TBL] [Abstract][Full Text] [Related]
7. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
Starnes HB; Patel AA; Stouffer GA
Drugs; 2011 Oct; 71(15):2009-30. PubMed ID: 21985168
[TBL] [Abstract][Full Text] [Related]
8. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
[TBL] [Abstract][Full Text] [Related]
9. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
Gilchrist IC
Clin Pharmacokinet; 2003; 42(8):703-20. PubMed ID: 12846593
[TBL] [Abstract][Full Text] [Related]
10. [Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment].
Mazaev AA; Naĭmushin IaA; Ruda MIa
Kardiologiia; 2006; 46(3):49-55. PubMed ID: 16710256
[TBL] [Abstract][Full Text] [Related]
11. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Harrington RA
Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
[TBL] [Abstract][Full Text] [Related]
12. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.
Phillips DR; Teng W; Arfsten A; Nannizzi-Alaimo L; White MM; Longhurst C; Shattil SJ; Randolph A; Jakubowski JA; Jennings LK; Scarborough RM
Circulation; 1997 Sep; 96(5):1488-94. PubMed ID: 9315536
[TBL] [Abstract][Full Text] [Related]
14. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
15. [Eptifibatide (Integrilin)].
Holmvang L; Grande P
Ugeskr Laeger; 2001 Jan; 163(4):468-72. PubMed ID: 11218791
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon.
Dyke C; Bhatia D
J Cardiovasc Surg (Torino); 1999 Aug; 40(4):505-16. PubMed ID: 10532207
[TBL] [Abstract][Full Text] [Related]
17. Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.
Ohman EM; Harrington RA; Lincoff AM; Kitt MM; Kleiman NS; Tcheng JE
Eur Heart J; 1995 Nov; 16 Suppl L():50-5. PubMed ID: 8869019
[TBL] [Abstract][Full Text] [Related]
18. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Mandak JS; Blankenship JC; Gardner LH; Berkowitz SD; Aguirre FV; Sigmon KN; Timmis GC; Gilchrist IC; McIvor M; Resar J; Weiner BH; George BS; Talley JD; Lincoff AM; Tcheng JE; Califf RM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1518-24. PubMed ID: 9626829
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: the circulate pilot trial.
Rocha-Singh KJ; Rutherford J
Catheter Cardiovasc Interv; 2005 Dec; 66(4):470-3. PubMed ID: 16284982
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
Storey RF; Wilcox RG; Heptinstall S
Circulation; 1998 Oct; 98(16):1616-21. PubMed ID: 9778326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]